NCT04692103: Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy

NCT04692103
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must be selected for an endocrine targeted therapy regimen for treatment of their breast cancer by the referring oncologist; Selected treatments may be part of experimental treatment protocols for which the patient would be separately consented
Exclusions: 
https://ClinicalTrials.gov/show/NCT04692103

Comments are closed.

Up ↑